---
document_datetime: 2025-08-13 15:40:31
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3418083
conversion_datetime: 2025-12-27 17:07:15.266495
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EXPAREL liposomal

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-----------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Renewal - 5 year /   | - Renewal | 22/05/2025                          | 23/07/2025                                  | SmPC, Annex                      | Based on the review of data on quality, safety and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/R/0000248989                      |                                                                                                                                                                                                                                                                                                                                              |            |     | II, Labelling and PL   | efficacy, the CHMP considered that the benefit-risk balance of EXPAREL liposomal in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                  |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000245314 | This was an application for a group of variations. B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.a Tightening of specification limits - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.d Other changes to a test procedure (including replacement or addition) - Accepted | 28/03/2025 | N/A |                        |                                                                                                                                                                                                                                                                               |
| PSUR / EMA/PSUR/0000248494            |                                                                                                                                                                                                                                                                                                                                              |            |     |                        | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing bupivacaine (liposomal formulations) remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |